Ten patients with acute leukemia (AL) in early relapse after allo-BMT were treated with a modified MEC (mitoxantrone, etoposide and Ara-C) regimen followed by donor PBPC collected after mobilization with G-CSF. Seven patients achieved CR or had normal hemopoietic reconstitution: two had an early relapse at days +53 and +48, two patients died from acute GVHD at days +31 and +96, one died of interstitial pneumonia at day +55, and two patients experienced long-term survival. One patient with refractory disease and nodal involvement who did not respond to the first BMT had overt expansion of the leukemia at day +36; one patient with Ph+ ALL and one with ANLL evolving from MDS, both with skin involvement, had blast cells in peripheral blood at day +27 and +26, respectively. Transient cytopenia occurred in all patients; a normal granulocyte and platelet count was achieved within 3 weeks in all patients but one; acute GVHD occurred in six patients, and four had chronic GVHD. This approach is feasible in patients in early relapse after allo-BMT. It assists prompt re-establishment of normal donor hematopoiesis avoiding the prolonged cytopenia observed after donor lymphocyte infusion in AL patients relapsed after allo-BMT. Keywords: PBPC; graft-versus-leukemia; relapse after allo-BMT; allogeneic bone marrow transplantation; acute leukemia Relapse after allogeneic bone marrow transplantation (allo-BMT) is an adverse event occurring in 21-36% of patients with acute leukemia (AL).
Relapse after allogeneic bone marrow transplantation (allo-BMT) is an adverse event occurring in 21-36% of patients with acute leukemia (AL). 1 Higher relapse rates of up to 70% have been observed in patients with advanced disease or in those receiving T-depleted graft. 2 Response to conventional chemotherapy is poor 1 and a second BMT is successful only in patients with late relapse. [3] [4] [5] Some authors have proposed new strategies aimed at stimulating donor hematopoiesis 6 or at potentiating the graft-versus-leukemia
Correspondence: Dr EP Alessandrino, Centro Trapianti di Midollo Osseo, Istituto di Ematologia, IRCCS Policlinico S Matteo, 27100 Pavia, Italy Received 1 July 1998; accepted 22 October 1998 (GVL) effect by infusion of donor immunocompetent cells 7, 8 or by using human recombinant interleukin-2 in vivo. 9 We report 10 cases of AL in relapse after allo-BMT treated by standard chemotherapy followed by the infusion of donor peripheral blood progenitor cells (PBPC) collected by leukapheresis after mobilization with G-CSF. One case of ANLL has been previously reported. 10 
Methods

Patient characteristics and BMT procedures
Ten patients with AL underwent an allo-BMT from an HLA-identical sibling. Nine received bone marrow cells while one patient had a PBPC transplant. Seven patients had ANLL, three with a previous history of myelodysplastic syndrome (MDS); in all cases but one, various cytogenetic abnormalities were found. Three patients had acute lymphocytic leukemia (ALL), two with t(9;22) translocation. The median age was 32 years (range 19-48); six were female, four male. Two patients received their transplant in first or second complete remission (CR); the remainder were in partial remission (PR) (one patient), had resistant disease (RD) (one patient), were in first or second relapse (five patients) or had active untreated disease (one patient).
Conditioning consisted of TBI and cyclophosphamide in four patients, busulfan and cyclophosphamide in two patients, while four patients received busulfan, etoposide and cyclophosphamide.
Graft-versus-host disease (GVHD) prophylaxis was cyclosporin A (CsA), methotrexate (MTX) and methylprednisolone (MP) in six patients while the remainder received CsA with low dose of MP. Patient characteristics and status of disease at transplant are summarized in Table 1 . Relapse was defined as the presence of more than 5% of leukemic cells in bone marrow samples. One patient with ANLL after MDS relapsed on day +104 and seven patients relapsed between days +120 and +365. One patient with extensive chronic GVHD had a relapse on day +1550 from BMT (he did not undergo a second transplant due to poor performance status). One patient with resistant disease failed to reach remission after transplant: he entered the study at day +40 from BMT. In three cases bone marrow relapse was This patient has been previously described. 10 associated with skin or nodal involvement. Grade I acute GVHD occurred in three cases; only one patient who received an allogeneic PBPC transplant had grade II acute GVHD followed by limited early chronic GVHD.
Treatment of relapse
Patients gave their informed consent, previously approved by the institutional review board. Nine patients received a three-drug regimen consisting of mitoxantrone 8 mg/m 2 /day for 5 days intravenously, etoposide 60 mg/m 2 /day intravenous 1 h infusion for 5 days and Ara-C 1 g/m 2 /day intravenous infusion over 6 h for 5 days. Two days later patients received the donor PBPC infusion. One patient had etoposide 80 mg/m 2 /day and mitoxantrone 8 mg/m 2 /day for 5 days. 11 All patients received at least 4 × 10 8 /kg mononuclear cells and a minimum of 2 × 10 6 /kg CD34 + cells. Only one patient received G-CSF at a dose of 5 g/kg/day i.v. after infusion until the WBC count reached 3 × 10 9 /l. GVHD was scored according to standard criteria. 12 No GVHD prophylaxis was given. Acute GVHD was treated with intravenous CsA and MP. CsA was given at a dose of 3 mg/kg/day over 12 h, intravenously, maintained at 1 mg/kg/day in responsive patients. MP was administered at a dose of 5 mg/kg/day for 4 days; the dose was then lowered to 2.5 mg/kg/day for 4 days and afterwards tapered to reach a minimum dose of 0.2 mg/kg/day.
PBPC mobilization and collection
Donor characteristics are shown in Table 2 . The median age was 30 years (range 24-47). Three were female and seven male. Five were sex mismatched with their recipients. Mobilization was with G-CSF and its potential risks were explained in detail; written informed consent was obtained from the donors according to the institutional guidelines.
Donors were treated with a daily subcutaneous injection of 5 g of G-CSF per kilogram body weight for 5 or 6 consecutive days. Leukapheresis was started on day 5 or 6 of G-CSF administration using the Cobe spectra apheresis system (Cobe Laboratories, Lakewood, CO, USA). Nine or 10 l of blood were processed using cubital veins in all cases. Progenitor cells were infused without further manipulation.
Cytogenetic analysis and fluorescence in situ hybridization
Serial cytogenetic studies were performed on marrow aspirates before treatment, and thereafter according to standard techniques. Twenty-five metaphases were analyzed if possible and reported according to standard nomenclature. 13 Patients receiving PBPC from sex-mismatched donors were assessed at different time points for hematopoietic chimerism using conventional cytogenetic tests or fluorescence in situ hybridization for sex chromosomes (X-Y FISH) ( Table  3) . In situ hybridization was performed on bone marrow cells already prepared for cytogenetic studies. Dual-colour FISH was carried out before therapy, at the time of engraftment and every time patients underwent bone marrow aspiration. In order to determine the confidence limits, sensitivity and specificity of the technique, we followed the approach of Dewald et al. 14 In our experience the normal range for XX cells in males was fixed at up to 0.791 Ϯ 0.013% and that for XY cells in females was fixed at up to 0.477 Ϯ 0.03%. The mean percentage of host and recipient cells was always corrected for the cut-offs reported above. Hybridization signals were counted in 1000 inter-phase cells with a fluorescence microscope equipped with a dual-pass filter.
Assessment of response
Effect of chemotherapy and donor PBPC infusion was assessed by evaluation of blood and bone marrow morphology. Complete hematological response was defined as a granulocyte count above 1 ϫ 10 9 /l in peripheral blood with normal bone marrow showing less than 5% of blast cells for at least 4 weeks. Minimal residual disease was detected by clonal and host specific markers using cytogenetic analysis and/or in situ hybridization. Bone marrow was aspirated 1, 3, 6 months after therapy or more frequently if clinically indicated.
Results
Seven patients achieved CR or had normal hemopoietic reconstitution: two of them experienced early relapse discovered at days +53 and +48, two died of acute GVHD at day +31 and at day +96, one patient died of interstitial pneumonia at day +55, the remaining two patients experienced long-term survival. One patient with refractory disease and nodal involvement who did not achieve any response to first BMT had overt expansion of the leukemic clone at day +36; one patient with Ph+ ALL and one with ANLL from MDS, both with skin involvement, had blast cells in the peripheral blood at days +27 and +26, respectively. Transient cytopenia occurred in all patients, followed by complete hematological reconstitution in responding patients (Table 4) . A normal granulocyte and platelet count was achieved within 3 weeks in all the patients but one; all had mild mucositis, and fever occurred in six out 10 patients.
GVHD and treatment-related mortality
Six out of 10 patients developed a grade II or more acute GVHD; they were treated with systemic MP and CsA; two died of acute GVHD at days +31 and +96, one died of interstitial pneumonia at day +55, while the other three patients developed lichenoid changes of the oral mucosa and other signs of extensive chronic GVHD. Two with ANLL are alive and well at days +650 and +900; the third, with Ph+ ALL, died of leukemia 170 days after relapse. This patient has been previously described.
10 LN = lymph nodes; MOF = multi-organ failure.
One patient had de novo early chronic GVHD; he relapsed at day +48 and died at day +93.
Chimerism
Data on chimerism by X-Y FISH were available in only five sex-mismatched couples; they are summarized in Table  3 . Data collected at the time of the hemopoietic recovery showed the persistence of host cells in all cases evaluated. A very low number of host cells was detected at day +15 in one long-term survivor where we were able to demonstrate complete chimerism 1 year after transplant; in the other long-term survivor who received this transplant from a sexmatched donor, conventional cytogenetic analysis failed to demonstrate the specific karyotypic abnormalities discovered at diagnosis. At first evaluation, the percentage of host cells was particularly high in two patients who had only a transient response to the treatment. In another patient with ALL, we noticed a progressive increase in host cells from day +30 onwards: he relapsed at day +53.
Discussion
Aggressive chemotherapy, second BMT and donor leukocyte infusion (DLI) are various options for leukemic relapse after allogeneic transplantation. Thirty per cent of patients may achieve remission after chemotherapy; however, patients who relapse early are lucky to gain a meaningful remission. 1 A second allogeneic BMT is recommended only in late relapses: patients relapsing within the first year of BMT experience the worst outcome. 3, 4 Encouraging results have been obtained with DLI;
15-17 the procedure may promote expansion of donor hematopoiesis by a GVL effect aimed at destroying the leukemic clone. The probability of response is high in chronic granulocytic leukemia (CGL) while in AL the results are poor. 15, 17 Acute GVHD and pancytopenia are the major causes of morbility and mortality: 15, 16 GVHD has been reported to be as high as 80%, 16 while pancytopenia occurs in 12-25% of patients. 17 In our study, patients with early relapse after transplantation received chemotherapy at standard doses followed by donor PBPC. We modified the MEC chemotherapy regimen reportedly effective in refractory AL. 18 Our intention was to use a combined approach aimed at controlling the tumor burden by chemotherapy, while PBPC were given to reinforce donor hematopoiesis and to induce GVL. Use of chemotherapy and PBPC in combination could provide a faster response than DLI alone recently reported to result in a median time to remission of 34 days (range 16-99 days) in AL and 85 days (range 28-241) in CGL. 17 We observed only transient cytopenia related to the use of chemotherapy followed by rapid reconstitution of donor hemopoiesis (median time: 15 days ranging from 12 to 26 days) (Table 4) .
In a recent study Glass et al 19 reported comparable results in six patients with acute leukemia in relapse after allo-BMT, treated by chemotherapy and PBPC infusion (three cases) or PBPC alone. They all achieved a short CR with a median duration of 24 weeks.
PBPC mobilized by hemopoietic growth factors are increasingly employed in allogeneic BMT. [20] [21] [22] [23] [24] [25] We gave 10 healthy donors 5 g/kg of G-CSF subcutaneously as a mobilizing agent; one or two leukaphereses provided an adequate yield of progenitor cells, with a high number of CD3 + cells. The high concentration of T cells in PBPC collections caused some concern with regard to the risk of severe GVHD, but several reports suggest that, in allogeneic PBPC transplantation, incidence of acute GVHD is not increased. [20] [21] [22] [23] Mechanisms to account for the unexpected low incidence of acute GVHD are being explored:
26 in mice, G-CSF was found to switch donor T cells toward a type 2 T-helper response with decrease of IL-2 and IFN-␥ and reduction in acute GVHD. 27 Although recent experimental data show an improved GVL effect in a murine model receiving a PBPC transplantation, 28 it is still unclear if this G-CSF-induced immunological pattern may have an impact on the human GVL potential.
In the present study six out of 10 patients developed acute GVHD and three had chronic GVHD. The incidence of acute GVHD was high, probably due to the lack of any GVHD prophylaxis following PBPC infusion; attempts to reduce GVHD without losing the GVL effect are worthwhile. The relationship between GVHD and GVL has been demonstrated by Weiden et al, 29 however, the precise interaction is still unclear. A study by Sullivan et al 30 failed to prove any modifications in relapse rate in AL patients specifically treated with DLI; recently some data in ANLL patients treated by T cell-depleted allograft support the hypothesis that almost complete elimination of acute and chronic GVHD may not compromise the antileukemic effect. 31, 32 In our study, the long-term survivors experienced acute and chronic GVHD. The only long-term responders had ANLL, while patients with ALL died early in relapse; these data seem to confirm the observation of others who have failed to demonstrate an adequate GVL effect in ALL. 2, 15 Treatment with standard chemotherapy and PBPC infusion is feasible in AL patients in relapse after allo-BMT; it favors prompt re-establishment of normal donor hematopoiesis, avoiding the prolonged cytopenia observed after treatment with DLI. 15, 17 On the basis of our data, this approach does not seem advisable in patients with primary resistant disease who never reached stable complete chimerism after the first transplant or in those with extramedullary relapse. Further attempts to improve the efficacy of this procedure should include mild immunosuppression after transplant to decrease the incidence of acute GVHD.
